Lazertinib
Sign in to save this workspacePrimary targets: EGFR · FDA status: FDA Approved
Selectivity scorecard
KISS
97.47
Gini
0.674
CATDS
0.022
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Lazertinib. Strongest target: EGFR at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | EGFR | 100.0% | 0.0% |
| 2 | ERBB2_HER2 | 99.7% | 0.3% |
| 3 | BLK | 99.0% | 1.0% |
| 4 | ERBB4_HER4 | 99.0% | 1.0% |
| 5 | JAK3 | 97.7% | 2.3% |
| 6 | FER | 97.7% | 2.3% |
| 7 | ROS_ROS1 | 97.0% | 3.0% |
| 8 | TXK | 97.0% | 3.0% |
| 9 | MLK1_MAP3K9 | 94.3% | 5.7% |
| 10 | MKK7 | 93.8% | 6.2% |
| 11 | ITK | 84.0% | 16.0% |
| 12 | AXL | 81.1% | 18.9% |
| 13 | MLK3_MAP3K11 | 79.5% | 20.5% |
| 14 | BTK | 77.1% | 22.9% |
| 15 | RIPK2 | 70.4% | 29.6% |
| 16 | TNK1 | 68.2% | 31.8% |
| 17 | SYK | 66.4% | 33.6% |
| 18 | EPHA6 | 63.3% | 36.7% |
| 19 | BMX_ETK | 58.9% | 41.1% |
| 20 | RET | 57.0% | 43.0% |
Selectivity landscape
Where Lazertinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Lazertinib.
Atlas insights for Lazertinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 1285.78 | |
| ALLOGRAFT_REJECTION | 4394.76 | |
| ANDROGEN_RESPONSE | 1235.13 | |
| ANGIOGENESIS | 876.24 | |
| APICAL_JUNCTION | 4590.86 | |
| APICAL_SURFACE | 482.07 | |
| APOPTOSIS | 3084.99 | |
| BILE_ACID_METABOLISM | 745.86 | |
| CHOLESTEROL_HOMEOSTASIS | 879.98 | |
| COAGULATION | 520.06 | |
| COMPLEMENT | 3173.06 | |
| DNA_REPAIR | 902.53 | |
| E2F_TARGETS | 2231.86 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 1012.17 | |
| ESTROGEN_RESPONSE_EARLY | 1590.32 | |
| ESTROGEN_RESPONSE_LATE | 1267.96 | |
| FATTY_ACID_METABOLISM | 276.57 | |
| G2M_CHECKPOINT | 1980.10 | |
| GLYCOLYSIS | 1306.04 | |
| HEDGEHOG_SIGNALING | 653.07 | |
| HEME_METABOLISM | 919.98 | |
| HYPOXIA | 1844.17 | |
| IL2_STAT5_SIGNALING | 1378.24 | |
| IL6_JAK_STAT3_SIGNALING | 2613.57 | |
| INFLAMMATORY_RESPONSE | 2927.40 | |
| INTERFERON_ALPHA_RESPONSE | 362.63 | |
| INTERFERON_GAMMA_RESPONSE | 3617.66 | |
| KRAS_SIGNALING_DN | 430.64 | |
| KRAS_SIGNALING_UP | 1792.51 | |
| MITOTIC_SPINDLE | 3041.20 | |
| MTORC1_SIGNALING | 1628.35 | |
| MYC_TARGETS_V1 | 1375.56 | |
| MYC_TARGETS_V2 | 268.11 | |
| MYOGENESIS | 1401.00 | |
| NOTCH_SIGNALING | 269.31 | |
| OXIDATIVE_PHOSPHORYLATION | 620.00 | |
| P53_PATHWAY | 1480.96 | |
| PANCREAS_BETA_CELLS | 135.12 | |
| PEROXISOME | 471.79 | |
| PI3K_AKT_MTOR_SIGNALING | 4248.71 | |
| PROTEIN_SECRETION | 1043.18 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 252.17 | |
| SPERMATOGENESIS | 752.28 | |
| TGF_BETA_SIGNALING | 1010.46 | |
| TNFA_SIGNALING_VIA_NFKB | 2592.26 | |
| UNFOLDED_PROTEIN_RESPONSE | 782.72 | |
| UV_RESPONSE_DN | 1996.69 | |
| UV_RESPONSE_UP | 1882.72 | |
| WNT_BETA_CATENIN_SIGNALING | 1117.64 | |
| XENOBIOTIC_METABOLISM | 1065.06 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.844 |
| SRR23303752 | — | 0.843 |
| SRR10899984 | — | 0.835 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.831 |
| aMVAC.P_005_TURBT_S223 | — | 0.830 |
Annotations
Sign in to read and post annotations.
Loading…